Rigel Pharmaceuticals Releases Comprehensive Five-Year Findings on REZLIDHIA® for R/R mIDH1 AML Treatment Rigel Pharmaceuticals has published final five-year results demonstrating the efficacy and safety of REZLIDHIA® in patients with R/R mIDH1 AML, offering hope for improved outcomes.

Rigel Pharmaceuticals Releases Comprehensive Five-Year Findings on REZLIDHIA® for R/R mIDH1 AML Treatment #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #mIDH1_AML

Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences Rigel Pharmaceuticals reveals upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA Congress, showcasing vital data on treatments for cancer and blood disorders.

Rigel Pharmaceuticals to Present Key Data at ASCO and EHA 2025 Conferences #United_States #South_San_Francisco #Rigel_Pharmaceuticals #REZLIDHIA #GAVRETO

Rigel Pharmaceuticals Releases Impressive Q4 and Full Year 2024 Financial Results Amidst Strong Business Expansion Rigel Pharmaceuticals reports significant revenue growth for Q4 2024, driven by strong product sales and successful regulatory achievements, projecting a promising 2025 outlook.

Rigel Pharmaceuticals Releases Impressive Q4 and Full Year 2024 Financial Results Amidst Strong Business Expansion #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA

Rigel Pharmaceuticals Reflects on 2024 Milestones and Sets Ambitious Goals for 2025 Rigel Pharmaceuticals has announced a successful 2024 with significant revenue growth, new product sales, and a hopeful outlook for 2025 as they continue to expand their hematology and oncology pipeline.

Rigel Pharmaceuticals Reflects on 2024 Milestones and Sets Ambitious Goals for 2025 #USA #South_San_Francisco #Rigel_Pharmaceuticals #TAVALISSE #REZLIDHIA